Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S.

Eur J Cancer. 2018 Nov 12;105:88-102. doi: 10.1016/j.ejca.2018.09.027. [Epub ahead of print]

PMID:
30439628
2.

Non-smoking, non-drinking elderly females, a 5 year follow-up of a clinically distinct cohort of oral squamous cell carcinoma patients.

DeAngelis A, Breik O, Koo K, Iseli T, Nastri A, Fua T, Rischin D, McCullough M, Wiesenfeld D.

Oral Oncol. 2018 Nov;86:113-120. doi: 10.1016/j.oraloncology.2018.09.004. Epub 2018 Sep 20.

PMID:
30409291
3.

Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103).

Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D; For ANZGOG and HCRN Collaborative Groups.

Cancer Chemother Pharmacol. 2018 Oct 27. doi: 10.1007/s00280-018-3706-5. [Epub ahead of print]

PMID:
30368585
4.

Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline.

Fakhry C, Lacchetti C, Rooper LM, Jordan RC, Rischin D, Sturgis EM, Bell D, Lingen MW, Harichand-Herdt S, Thibo J, Zevallos J, Perez-Ordonez B.

J Clin Oncol. 2018 Sep 6:JCO1800684. doi: 10.1200/JCO.18.00684. [Epub ahead of print]

PMID:
30188786
5.

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre.

Moloney M, Faulkner D, Link E, Rischin D, Solomon B, Lim AM, Zalcberg JR, Jefford M, Michael M.

Cancer Chemother Pharmacol. 2018 Nov;82(5):865-876. doi: 10.1007/s00280-018-3679-4. Epub 2018 Sep 3.

PMID:
30178115
6.

A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies.

Maleki S, Alexander M, Fua T, Liu C, Rischin D, Lingaratnam S.

J Oncol Pharm Pract. 2018 Jan 1:1078155218783814. doi: 10.1177/1078155218783814. [Epub ahead of print]

PMID:
29938594
7.

Diabetes associated with immune checkpoint inhibition: presentation and management challenges.

Galligan A, Xu W, Fourlanos S, Nankervis A, Chiang C, Mant AM, Parente P, Rischin D, Krishnamurthy B, Sandhu S, Colman PG.

Diabet Med. 2018 Jun 16. doi: 10.1111/dme.13762. [Epub ahead of print]

PMID:
29908076
8.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.

PMID:
29863979
9.

Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.

Porceddu SV, Bressel M, Poulsen MG, Stoneley A, Veness MJ, Kenny LM, Wratten C, Corry J, Cooper S, Fogarty GB, Collins M, Collins MK, Macann AMJ, Milross CG, Penniment MG, Liu HY, King MT, Panizza BJ, Rischin D.

J Clin Oncol. 2018 May 1;36(13):1275-1283. doi: 10.1200/JCO.2017.77.0941. Epub 2018 Mar 14.

PMID:
29537906
10.

Unilateral radiotherapy treatment for p16/human papillomavirus-positive squamous cell carcinoma of unknown primary in the head and neck.

Tiong A, Rischin D, Young RJ, Herschtal A, Solomon B, D'Costa I, Fua T, Liu C, Coleman A, Kleid S, Dixon BJ, Corry J.

Laryngoscope. 2018 Sep;128(9):2076-2083. doi: 10.1002/lary.27131. Epub 2018 Feb 26.

PMID:
29481710
11.

Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03.

Poulsen M, Macfarlane D, Veness M, Estall V, Hruby G, Kumar M, Pullar A, Tripcony L, Rischin D.

J Med Imaging Radiat Oncol. 2018 Jun;62(3):412-419. doi: 10.1111/1754-9485.12705. Epub 2018 Feb 5.

PMID:
29405630
12.

High-Dose Cisplatin for Head and Neck Cancer Lives On.

Thai AA, Rischin D.

J Clin Oncol. 2018 Apr 10;36(11):1055-1057. doi: 10.1200/JCO.2017.76.8614. Epub 2018 Feb 2. No abstract available.

PMID:
29394123
13.

Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma.

Solomon B, Young RJ, Bressel M, Urban D, Hendry S, Thai A, Angel C, Haddad A, Kowanetz M, Fua T, Corry J, Fox S, Rischin D.

Cancer Immunol Res. 2018 Jan 29. doi: 10.1158/2326-6066.CIR-17-0299. [Epub ahead of print]

PMID:
29378694
14.

Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.

Solomon B, Young RJ, Rischin D.

Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240. doi: 10.1016/j.semcancer.2018.01.008. Epub 2018 Jan 31. Review.

PMID:
29355614
15.

The role of human papillomavirus in p16-positive oral cancers.

Belobrov S, Cornall AM, Young RJ, Koo K, Angel C, Wiesenfeld D, Rischin D, Garland SM, McCullough M.

J Oral Pathol Med. 2018 Jan;47(1):18-24. doi: 10.1111/jop.12649. Epub 2017 Oct 30.

PMID:
29024035
16.

Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG.

Le QT, Welch JJ, Vermorken JB, Rischin D, Mehanna H; all HNCIG investigators.

Oral Oncol. 2017 Aug;71:180-183. doi: 10.1016/j.oraloncology.2017.05.022. Epub 2017 Jun 22.

PMID:
28648362
17.

Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.

Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV, Wratten C, Rischin D.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):948-954. doi: 10.1016/j.ijrobp.2017.02.088. Epub 2017 Feb 24.

PMID:
28483336
18.

Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation.

Kanjanapan Y, Deb S, Young RJ, Bressel M, Mileshkin L, Rischin D, Hofman MS, Narayan K, Siva S.

Clin Transl Radiat Oncol. 2017 Feb 8;2:53-58. doi: 10.1016/j.ctro.2017.01.003. eCollection 2017 Feb.

19.

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB.

Front Oncol. 2016 Oct 31;6:232. eCollection 2016.

20.

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD.

Clin Cancer Res. 2017 Apr 1;23(7):1862-1874. doi: 10.1158/1078-0432.CCR-16-0620. Epub 2016 Sep 23.

21.

Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services.

Alexander M, Beattie-Manning R, Blum R, Byrne J, Hornby C, Kearny C, Love N, McGlashan J, McKiernan S, Milar JL, Murray D, Opat S, Parente P, Thomas J, Tweddle N, Underhill C, Whitfield K, Kirsa S, Rischin D.

Intern Med J. 2016 Aug;46(8):964-9. doi: 10.1111/imj.13157.

PMID:
27553996
22.

Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas.

Lim AM, Wong NC, Pidsley R, Zotenko E, Corry J, Dobrovic A, Clark SJ, Rischin D, Solomon B.

Clin Epigenetics. 2016 Jul 18;8:74. doi: 10.1186/s13148-016-0235-0. eCollection 2016.

23.

Recent Insights and Advances in the Management of Merkel Cell Carcinoma.

Banks PD, Sandhu S, Gyorki DE, Johnston ML, Rischin D.

J Oncol Pract. 2016 Jul;12(7):637-46. doi: 10.1200/JOP.2016.013367. Review.

PMID:
27407160
24.

Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice.

Alexander M, Blum R, Burbury K, Coutsouvelis J, Dooley M, Fazil O, Griffiths T, Ismail H, Joshi S, Love N, Opat S, Parente P, Porter N, Ross E, Siderov J, Thomas P, White S, Kirsa S, Rischin D.

Intern Med J. 2017 Jan;47(1):16-34. doi: 10.1111/imj.13190. Review.

PMID:
27396268
25.

Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART).

Ringash J, Fisher R, Peters L, Trotti A, O'Sullivan B, Corry J, Kenny L, Nuyts S, Wratten C, Rischin D.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):678-686. doi: 10.1016/j.ijrobp.2016.03.017. Epub 2016 Mar 23. Erratum in: Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):244.

PMID:
27209505
26.

BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.

Lim AM, Taylor GR, Fellowes A, Cameron L, Lee B, Hicks RJ, McArthur GA, Angel C, Solomon B, Rischin D.

J Natl Compr Canc Netw. 2016 Mar;14(3):249-54. Epub 2016 Mar 8.

PMID:
26957611
27.

Individualised mindfulness-based stress reduction for head and neck cancer patients undergoing radiotherapy of curative intent: a descriptive pilot study.

Pollard A, Burchell JL, Castle D, Neilson K, Ftanou M, Corry J, Rischin D, Kissane DW, Krishnasamy M, Carlson LE, Couper J.

Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12474. Epub 2016 Mar 7.

PMID:
26947583
28.

p16-positive lymph node metastases from cutaneous head and neck squamous cell carcinoma: No association with high-risk human papillomavirus or prognosis and implications for the workup of the unknown primary.

McDowell LJ, Young RJ, Johnston ML, Tan TJ, Kleid S, Liu CS, Bressel M, Estall V, Rischin D, Solomon B, Corry J.

Cancer. 2016 Apr 15;122(8):1201-8. doi: 10.1002/cncr.29901. Epub 2016 Feb 16.

29.

PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Rischin D, Spigel DR, Adkins D, Wein R, Arnold S, Singhal N, Lee O, Murugappan S.

Head Neck. 2016 Apr;38 Suppl 1:E1756-61. doi: 10.1002/hed.24311. Epub 2015 Dec 17.

PMID:
26681429
30.

Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome.

Graves EE, Hicks RJ, Binns D, Bressel M, Le QT, Peters L, Young RJ, Rischin D.

Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):617-25. doi: 10.1007/s00259-015-3247-7. Epub 2015 Nov 18.

31.

Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma.

Urban D, Corry J, Solomon B, Lim AM, Fua T, Coleman A, D'Costa I, Tiong A, Liu C, Peters LJ, Rischin D.

Head Neck. 2016 Apr;38 Suppl 1:E1117-21. doi: 10.1002/hed.24169. Epub 2015 Oct 13.

PMID:
26461454
32.

Overview of Advances in Head and Neck Cancer.

Rischin D, Ferris RL, Le QT.

J Clin Oncol. 2015 Oct 10;33(29):3225-6. doi: 10.1200/JCO.2015.63.6761. Epub 2015 Sep 8. Review. No abstract available.

PMID:
26351331
33.

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.

Hunter FW, Young RJ, Shalev Z, Vellanki RN, Wang J, Gu Y, Joshi N, Sreebhavan S, Weinreb I, Goldstein DP, Moffat J, Ketela T, Brown KR, Koritzinsky M, Solomon B, Rischin D, Wilson WR, Wouters BG.

Cancer Res. 2015 Oct 1;75(19):4211-23. doi: 10.1158/0008-5472.CAN-15-1107. Epub 2015 Aug 21.

34.

¹⁸F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data.

Siva S, Deb S, Young RJ, Hicks RJ, Callahan J, Bressel M, Mileshkin L, Rischin D, Bernshaw D, Narayan K.

Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1825-32. doi: 10.1007/s00259-015-3112-8. Epub 2015 Jul 15.

PMID:
26173619
35.

Merkel cell carcinoma: emerging biology, current approaches, and future directions.

Tothill R, Estall V, Rischin D.

Am Soc Clin Oncol Educ Book. 2015:e519-26. doi: 10.14694/EdBook_AM.2015.35.e519. Review.

36.

Safety and cost analysis of an (18)FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation.

Shah K, Te Marvelde L, Collins M, De Abreu Lourenco R, D'Costa I, Coleman A, Fua T, Liu C, Rischin D, Lau E, Corry J.

Oral Oncol. 2015 May;51(5):529-35. doi: 10.1016/j.oraloncology.2015.02.005. Epub 2015 Mar 6.

PMID:
25754169
37.

Abiraterone in metastatic salivary duct carcinoma.

Urban D, Rischin D, Angel C, D'Costa I, Solomon B.

J Natl Compr Canc Netw. 2015 Mar;13(3):288-90.

PMID:
25736005
38.

Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma.

Young RJ, Urban D, Angel C, Corry J, Lyons B, Vallance N, Kleid S, Iseli TA, Solomon B, Rischin D.

Br J Cancer. 2015 Mar 17;112(6):1098-104. doi: 10.1038/bjc.2015.59.

39.

Impact of center size and experience on outcomes in head and neck cancer.

Corry J, Peters LJ, Rischin D.

J Clin Oncol. 2015 Jan 10;33(2):138-40. doi: 10.1200/JCO.2014.58.2239. Epub 2014 Dec 8. No abstract available.

PMID:
25488964
40.

Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.

Lingaratnam SM, Slavin MA, Thursky KA, Teh BW, Haeusler GM, Seymour JF, Rischin D, Worth LJ.

Leuk Lymphoma. 2015 Jan;56(1):157-62. doi: 10.3109/10428194.2014.911861.

PMID:
24717111
41.

Ovarian Growing Teratoma Syndrome With Spuriously Elevated α-Fetoprotein.

Pendlebury A, Rischin D, Ireland-Jenkin K, Toner GC, Grant P.

J Clin Oncol. 2015 Aug 20;33(24):e99-100. doi: 10.1200/JCO.2013.49.8998. Epub 2014 Apr 7. No abstract available.

PMID:
24711556
42.

What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?

Urban D, Corry J, Rischin D.

Cancer. 2014 May 15;120(10):1462-70. doi: 10.1002/cncr.28595. Epub 2014 Feb 27. Review.

43.

Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.

Trinkaus ME, Hicks RJ, Young RJ, Peters LJ, Solomon B, Bressel M, Corry J, Fisher R, Binns D, McArthur GA, Rischin D.

J Med Imaging Radiat Oncol. 2014 Feb;58(1):89-97. doi: 10.1111/1754-9485.12155.

PMID:
24529061
44.

Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.

Lim AM, Do H, Young RJ, Wong SQ, Angel C, Collins M, Takano EA, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Fox SB, Rischin D, Dobrovic A, Solomon B.

Int J Cancer. 2014 Aug 15;135(4):887-95. doi: 10.1002/ijc.28727. Epub 2014 Jan 30.

45.

Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome.

Lim AM, Candiloro IL, Wong N, Collins M, Do H, Takano EA, Angel C, Young RJ, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Rischin D, Solomon B, Dobrovic A.

Clin Epigenetics. 2014 Dec 9;6(1):22. doi: 10.1186/1868-7083-6-22. eCollection 2014.

46.

T4 squamous cell carcinoma of the oral tongue without mandibular involvement: surgery or chemoradiotherapy?

McDowell L, Collins M, Kleid S, Rischin D, Corry J.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Feb;117(2):163-9. doi: 10.1016/j.oooo.2013.09.005. Epub 2013 Nov 23.

PMID:
24275355
47.

Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.

Etemadmoghadam D, Au-Yeung G, Wall M, Mitchell C, Kansara M, Loehrer E, Batzios C, George J, Ftouni S, Weir BA, Carter S, Gresshoff I, Mileshkin L, Rischin D, Hahn WC, Waring PM, Getz G, Cullinane C, Campbell LJ, Bowtell DD.

Clin Cancer Res. 2013 Nov 1;19(21):5960-71. doi: 10.1158/1078-0432.CCR-13-1337. Epub 2013 Sep 4.

48.

Developing a performance data suite to facilitate lean improvement in a chemotherapy day unit.

Lingaratnam S, Murray D, Carle A, Kirsa SW, Paterson R, Rischin D.

J Oncol Pract. 2013 Jul;9(4):e115-21. doi: 10.1200/JOP.2012.000755. Epub 2013 Apr 9.

49.

Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose.

Dooley MJ, Poole SG, Rischin D.

Ann Oncol. 2013 Nov;24(11):2746-52. doi: 10.1093/annonc/mdt300. Epub 2013 Aug 7.

PMID:
23928359
50.

Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.

Trinkaus ME, Blum R, Rischin D, Callahan J, Bressel M, Segard T, Roselt P, Eu P, Binns D, MacManus MP, Ball D, Hicks RJ.

J Med Imaging Radiat Oncol. 2013 Aug;57(4):475-81. doi: 10.1111/1754-9485.12086. Epub 2013 Jun 14.

PMID:
23870348

Supplemental Content

Loading ...
Support Center